Daniel Markett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Markett has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Bruce Culbertson
Integrated Program in Cellular, Molecular, and Biomedical Studies, Columbia University Vagelos College of Physicians and Surgeons, New York, USA
2 shared publications - Hani Goodarzi
Department of Biochemistry and Biophysics, University of California, San Francisco, USA
2 shared publications - Kristle Garcia
Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, USA
2 shared publications Lisa Fish
Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, USA
2 shared publicationsAlbertas Navickas
Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, USA
1 shared publication- Albertas Navickas
Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA
1 shared publication
Latest Publications
- Open Access
- 11 May 2023
- Published by Springer Nature in Nature Cancer
- Vol. 4 (5) , 682-698
A sense-antisense RNA interaction promotes breast cancer metastasis via regulation of NQO1 expression
Antisense RNAs are ubiquitous in human cells, yet their role is largely unexplored. Here we profiled antisense RNAs in the MDA-MB-231 breast cancer cell line and its highly lung metastatic derivative. We identified one antisense RNA that drives cancer progression by upregulating the redox enzyme NADPH quinone dehydrogenase 1 (NQO1), and named it NQO1-AS. Knockdown of either NQO1 or NQO1-AS reduced lung colonization in a mouse model, and investigation into the role of NQO1 indicated that it is broadly protective against oxidative damage and ferroptosis. Breast cancer cells in the lung are dependent on this pathway, and this dependence can be exploited therapeutically by inducing ferroptosis while inhibiting NQO1. Together, our findings establish a role for NQO1-AS in the progression of breast cancer by regulating its sense mRNA post-transcriptionally. Because breast cancer predominantly affects females, the disease models used in this study are of female origin and the results are primarily applicable to females.
- 11 May 2023
- Published by Springer Nature in Nature Cancer
- Vol. 4 (5) , 682-698
Open AccessA sense-antisense RNA interaction promotes breast cancer metastasis via regulation of NQO1 expression
Antisense RNAs are ubiquitous in human cells, yet their role is largely unexplored. Here we profiled antisense RNAs in the MDA-MB-231 breast cancer cell line and its highly lung metastatic derivative. We identified one antisense RNA that drives cancer progression by upregulating the redox enzyme NADPH quinone dehydrogenase 1 (NQO1), and named it NQO1-AS. Knockdown of either NQO1 or NQO1-AS reduced lung colonization in a mouse model, and investigation into the role of NQO1 indicated that it is broadly protective against oxidative damage and ferroptosis. Breast cancer cells in the lung are dependent on this pathway, and this dependence can be exploited therapeutically by inducing ferroptosis while inhibiting NQO1. Together, our findings establish a role for NQO1-AS in the progression of breast cancer by regulating its sense mRNA post-transcriptionally. Because breast cancer predominantly affects females, the disease models used in this study are of female origin and the results are primarily applicable to females.
- Open Access
- 8 May 2023
- Published by Springer Nature in Nature Cell Biology
- Vol. 25 (6) , 892-903
An mRNA processing pathway suppresses metastasis by governing translational control from the nucleus
Cancer cells often co-opt post-transcriptional regulatory mechanisms to achieve pathologic expression of gene networks that drive metastasis. Translational control is a major regulatory hub in oncogenesis; however, its effects on cancer progression remain poorly understood. Here, to address this, we used ribosome profiling to compare genome-wide translation efficiencies of poorly and highly metastatic breast cancer cells and patient-derived xenografts. We developed dedicated regression-based methods to analyse ribosome profiling and alternative polyadenylation data, and identified heterogeneous nuclear ribonucleoprotein C (HNRNPC) as a translational controller of a specific mRNA regulon. We found that HNRNPC is downregulated in highly metastatic cells, which causes HNRNPC-bound mRNAs to undergo 3′ untranslated region lengthening and, subsequently, translational repression. We showed that modulating HNRNPC expression impacts the metastatic capacity of breast cancer cells in xenograft mouse models. In addition, the reduced expression of HNRNPC and its regulon is associated with the worse prognosis in breast cancer patient cohorts.
- 8 May 2023
- Published by Springer Nature in Nature Cell Biology
- Vol. 25 (6) , 892-903
Open AccessAn mRNA processing pathway suppresses metastasis by governing translational control from the nucleus
Cancer cells often co-opt post-transcriptional regulatory mechanisms to achieve pathologic expression of gene networks that drive metastasis. Translational control is a major regulatory hub in oncogenesis; however, its effects on cancer progression remain poorly understood. Here, to address this, we used ribosome profiling to compare genome-wide translation efficiencies of poorly and highly metastatic breast cancer cells and patient-derived xenografts. We developed dedicated regression-based methods to analyse ribosome profiling and alternative polyadenylation data, and identified heterogeneous nuclear ribonucleoprotein C (HNRNPC) as a translational controller of a specific mRNA regulon. We found that HNRNPC is downregulated in highly metastatic cells, which causes HNRNPC-bound mRNAs to undergo 3′ untranslated region lengthening and, subsequently, translational repression. We showed that modulating HNRNPC expression impacts the metastatic capacity of breast cancer cells in xenograft mouse models. In addition, the reduced expression of HNRNPC and its regulon is associated with the worse prognosis in breast cancer patient cohorts.